Success Metrics

Clinical Success Rate
73.3%

Based on 11 completed trials

Completion Rate
73%(11/15)
Active Trials
1(6%)
Results Posted
118%(13 trials)
Terminated
4(25%)

Phase Distribution

Ph phase_3
2
13%
Ph phase_4
5
31%
Ph phase_2
9
56%

Phase Distribution

0

Early Stage

9

Mid Stage

7

Late Stage

Phase Distribution16 total trials
Phase 2Efficacy & side effects
9(56.3%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
5(31.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.3%

11 of 15 finished

Non-Completion Rate

26.7%

4 ended early

Currently Active

1

trials recruiting

Total Trials

16

all time

Status Distribution
Active(1)
Completed(11)
Terminated(4)

Detailed Status

Completed11
Terminated4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
1
Success Rate
73.3%
Most Advanced
Phase 4

Trials by Phase

Phase 29 (56.3%)
Phase 32 (12.5%)
Phase 45 (31.3%)

Trials by Status

recruiting16%
completed1169%
terminated425%

Recent Activity

1 active trials
Showing 5 of 16
terminatedphase_4

Comparison of Potassium Binders in the ER

NCT04585542
recruitingphase_2

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

NCT05766839
terminatedphase_4

RELieving Increasing oEdema Due to Heart Failure

NCT04142788
completedphase_2

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
completedphase_3

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT04585542Phase 4

Comparison of Potassium Binders in the ER

Terminated
NCT05766839Phase 2

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Recruiting
NCT04142788Phase 4

RELieving Increasing oEdema Due to Heart Failure

Terminated
NCT03326583Phase 2

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

Completed
NCT03888066Phase 3

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Completed
NCT03087058Phase 2

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

Terminated
NCT03183778Phase 4

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

Completed
NCT01810939Phase 3

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

Completed
NCT01371747Phase 2

Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)

Completed
NCT00868439Phase 2

Evaluation of Patiromer in Heart Failure Patients

Completed
NCT02694744Phase 4

Patiromer With or Without Food for the Treatment of Hyperkalemia

Completed
NCT01130597Phase 2

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

Completed
NCT02033317Phase 2

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Terminated
NCT03071263Phase 2

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

Completed
NCT03799926Phase 2

Exploratory Study of ZG-801 for the Treatment of Hyperkalemia

Completed
NCT03229265Phase 4

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16